June 19, 2017 / 5:07 AM / 3 months ago

BRIEF-Asit Biotech discloses comments from the PEI on BTT009

June 19 (Reuters) - ASIT BIOTECH SA

* REPORTS ‍PAUL-EHRLICH-INSTITUT​ AND PUBLISHES DETAILED RESULTS CLINICAL FASE III STUDY WITH GP-ASIT+

* PEI AGREED THAT CPT1 REACTIVITY AT BASELINE MAY BE USED TO CHARACTERIZE AND IDENTIFY THE MOST APPROPRIATE PATIENTS IN A FUTURE PHASE III STUDY

* PEI GRANTED A SCIENTIFIC ADVICE SESSION TO ASIT BIOTECH TO REVIEW THE RESULTS OF BTT009 AND AGREE ON FURTHER CLINICAL AND REGULATORY DEVELOPMENTS‍​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below